Share this article
Share this article
ResearchAndMarkets.com's offering.
The global irritable bowel syndrome with diarrhea market is rising at a significant pace, projected to rise at a CAGR of 11.3% during the estimated period from 2020 to 2028, starting from US$ 423.3 Mn in 2019.
Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market. These approvals are viewed as a breakthrough step in the long struggle to discover an effective treatment for IBS-D.
Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off-label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand for Xifaxan during the forecast period. Drugs such as loperamide will experience a slack in demand due to the introduction of the said novel drugs.